Announcement • May 19
Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026 Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026, at 10:00 W. Europe Standard Time. Recent Insider Transactions • May 18
Chairman of the Supervisory Board recently bought €833m worth of stock On the 14th of May, Wilhelm Beier bought around 18m shares on-market at roughly €46.83 per share. This transaction increased Wilhelm's direct individual holding by 5x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Wilhelm has been a buyer over the last 12 months, purchasing a net total of €955m worth in shares. New Risk • May 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Austrian stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (111% net debt to equity). Share price has been volatile over the past 3 months (6.0% average weekly change). Reported Earnings • May 14
First quarter 2026 earnings released: EPS: €0.84 (vs €0.62 in 1Q 2025) First quarter 2026 results: EPS: €0.84 (up from €0.62 in 1Q 2025). Revenue: €318.9m (up 4.5% from 1Q 2025). Net income: €45.2m (up 35% from 1Q 2025). Profit margin: 14% (up from 11% in 1Q 2025). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in Europe. Declared Dividend • Apr 02
Dividend reduced to €0.88 Dividend of €0.88 is 2.2% lower than last year. Ex-date: 29th June 2026 Payment date: 1st July 2026 Dividend yield will be 1.9%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is well covered by both earnings (42% earnings payout ratio) and cash flows (29% cash payout ratio). The dividend has increased by an average of 2.3% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 38% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Apr 01
Dermapharm Holding SE announces Annual dividend, payable on July 01, 2026 Dermapharm Holding SE announced Annual dividend of EUR 0.8800 per share payable on July 01, 2026, ex-date on June 29, 2026 and record date on June 30, 2026. Announcement • Mar 11
Dermapharm Holding SE (XTRA:DMP) announces an Equity Buyback for 4,300,000 shares, representing 7.99% for €180.6 million. Dermapharm Holding SE (XTRA:DMP) announces a share repurchase program. Under the program, the company will repurchase up to 4,300,000 shares, representing 7.99% of the share capital of the Company. The shares will be repurchased at a price of €42 per share. The repurchased shares are intended to be cancelled. If more than 4,300,000 shares are tendered for repurchase into the offer, acceptances will be taken into account on a pro-rata basis in the ratio of 4,300,000 shares to the total number of shares tendered for repurchase by the shareholders. The offer ends, subject to an extension by the company, on March 24, 2026. Reported Earnings • Nov 15
Third quarter 2025 earnings released: EPS: €0.76 (vs €0.60 in 3Q 2024) Third quarter 2025 results: EPS: €0.76 (up from €0.60 in 3Q 2024). Revenue: €312.6m (flat on 3Q 2024). Net income: €41.2m (up 27% from 3Q 2024). Profit margin: 13% (up from 10% in 3Q 2024). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in Europe. New Risk • Sep 01
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 137% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (137% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Reported Earnings • Aug 26
Second quarter 2025 earnings released: EPS: €0.39 (vs €0.32 in 2Q 2024) Second quarter 2025 results: EPS: €0.39 (up from €0.32 in 2Q 2024). Revenue: €280.8m (down 1.0% from 2Q 2024). Net income: €20.9m (up 21% from 2Q 2024). Profit margin: 7.4% (up from 6.1% in 2Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Pharmaceuticals industry in Europe. Recent Insider Transactions • Jul 09
Chairman of the Supervisory Board recently bought €122m worth of stock On the 3rd of July, Wilhelm Beier bought around 3m shares on-market at roughly €34.94 per share. This transaction increased Wilhelm's direct individual holding by 22x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Wilhelm's only on-market trade for the last 12 months. Announcement • Jun 28
Dermapharm Holding SE Approves Annual Dividend Dermapharm Holding SE at its Annual General Meeting held on 26 June 2025, acted on the recommendation of the Board of Management and the Supervisory Board to distribute a dividend of EUR 0.90 per share carrying dividend rights. The total distribution amounts to EUR 48.5 million, representing a distribution ratio of approximately 43% of the consolidated net profit eligible for distribution. New Risk • May 23
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 17% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Announcement • May 16
Dermapharm Holding SE, Annual General Meeting, Jun 26, 2025 Dermapharm Holding SE, Annual General Meeting, Jun 26, 2025, at 10:00 W. Europe Standard Time. Reported Earnings • May 15
Full year 2024 earnings released: EPS: €2.11 (vs €1.16 in FY 2023) Full year 2024 results: EPS: €2.11 (up from €1.16 in FY 2023). Revenue: €1.20b (up 3.9% from FY 2023). Net income: €113.8m (up 82% from FY 2023). Profit margin: 9.5% (up from 5.4% in FY 2023). Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Pharmaceuticals industry in Europe. New Risk • May 15
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.5% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks High level of debt (140% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Reported Earnings • Apr 03
Full year 2024 earnings released: EPS: €2.11 (vs €1.16 in FY 2023) Full year 2024 results: EPS: €2.11 (up from €1.16 in FY 2023). Revenue: €1.20b (up 3.9% from FY 2023). Net income: €113.8m (up 82% from FY 2023). Profit margin: 9.5% (up from 5.4% in FY 2023). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Pharmaceuticals industry in Europe. Announcement • Jan 02
Dermapharm Holding SE to Report Fiscal Year 2024 Results on Mar 14, 2025 Dermapharm Holding SE announced that they will report fiscal year 2024 results on Mar 14, 2025 Valuation Update With 7 Day Price Move • Nov 21
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to €37.05, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 14x in the Pharmaceuticals industry in Europe. Reported Earnings • Nov 17
Third quarter 2024 earnings released: EPS: €0.60 (vs €0.46 in 3Q 2023) Third quarter 2024 results: EPS: €0.60 (up from €0.46 in 3Q 2023). Revenue: €337.1m (up 17% from 3Q 2023). Net income: €32.4m (up 30% from 3Q 2023). Profit margin: 9.6% (up from 8.6% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Pharmaceuticals industry in Europe. 
